Ontology highlight
ABSTRACT:
SUBMITTER: Lassman AB
PROVIDER: S-EPMC6303422 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature
Lassman Andrew B AB van den Bent Martin J MJ Gan Hui K HK Reardon David A DA Kumthekar Priya P Butowski Nicholas N Lwin Zarnie Z Mikkelsen Tom T Nabors Louis B LB Papadopoulos Kyriakos P KP Penas-Prado Marta M Simes John J Wheeler Helen H Walbert Tobias T Scott Andrew M AM Gomez Erica E Lee Ho-Jin HJ Roberts-Rapp Lisa L Xiong Hao H Ansell Peter J PJ Bain Earle E Holen Kyle D KD Maag David D Merrell Ryan R
Neuro-oncology 20190101 1
<h4>Background</h4>Patients with glioblastoma (GBM) have a dismal prognosis. Nearly all will relapse with no clear standard of care for recurrent disease (rGBM). Approximately 50% of patients have tumors harboring epidermal growth factor receptor (EGFR) amplification. The antibody-drug conjugate depatuxizumab mafodotin (depatux-m) binds cells with EGFR amplification, is internalized, and releases a microtubule toxin, killing the cell. Here we report efficacy, safety and pharmacokinetics (PK) of ...[more]